The University of Sydney and Agilent Technologies have formally opened their state-of-the-art Oxidative Stress Bioanalytical Facility (OSBF) in the Medical Foundation Building.
The University of Sydney and Agilent Technologies have formally opened their state-of-the-art Oxidative Stress Bioanalytical Facility (OSBF) in the Medical Foundation Building.
The OSBF, funded in part by an ARC LIEF grant with Agilent as the commercial partner, is expected to provide a state-of-the-art facility at the University of Sydney for researchers to develop cutting-edge technology and unique local skills, create a platform for major national and international research collaborations and enable Australia to maintain a leading position in Redox-related research in biology and medicine.
“We’re extremely pleased to have this unique opportunity to partner with Agilent Technologies to establish this world-class facility that places us at the forefront of Redox-related research on a worldwide level,” said Professor Roland Stocker, founder of the Bosch OSBF. “This facility will also allow us to complement and integrate with existing facilities in this area of research in Australia.”
“The Bosch OSBF is unique in the world and it provides our researchers with a powerful platform to advance our understanding of the many diseases we study,” said Professor Jonathan Stone, the Executive Director of the Bosch Institute. “In addition, the lab has been equipped with the new Agilent 1290 HPLC coupled with the Agilent 6460 Triple Quadrupole Mass Spectrometer, which will further Redox-related research.”
For further information visit www.bosch.org.au/
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Investigating Synthetic Cathinone Positional Isomers using LC–EAD-MS
November 7th 2024Peng Che fom Vrije Universiteit Amsterdam in the Netherlands discusses the benefits of hyphenating liquid chromatography (LC) with electron activated dissociation mass spectrometry (EAD-MS) to analyze cathinone positional isomers.